Beyin metastazı yapmış akciğer kanserli hastalarda iki farklı radyoterapi şemasının karşılaştırılması

Palyatif amaçlı radyoterapide genellikle kısa radyoterapi şemaları tercih edilmektedir. Beyin metastazı yapmış akciğer kanserli hastalarda rutin olarak uygulanan bir uzun ve bir kısa radyoterapi şeması sağ kalım ve palyatif cevap açısından retrospektif olarak karşılaştırıldı. Ocak 2001 ile Aralık 2004 tarihleri arasında merkezimize başvuran akciğer kanseri, beyin metastazlı 44 hastanın 28’i uzun radyoterapi şeması (3000 cGy/10 fraksiyon/2 hafta) ve 16’sı kısa radyoterapi şeması (2000 cGy/5 fraksiyon/1 hafta) ile tedavi edilmişti. Hastaların yaş, cinsiyet, histopatolojik tanı ve performans durumları iki grupta benzerdi. Medyan sağ kalım süresi 3,5 ay olarak izlendi ve sağ kalım eğrisi iki grup arasında benzerdi. Sonuç olarak daha ekonomik ve kolay olan kısa radyoterapi şeması bu büyük bir hasta grubu için yaygın olarak tercih edilebilir.

Anahtar Kelimeler:

Akciğer neoplazmları, Neoplazm metastazı, Radyoterapi, Beyin neoplazmları, Palyatif bakım, Sağkalım oranı

Comparison of two different radiotherapy schedules in lung cancer patients with brain metastasis

Short irradiation schedules are generally preferred in palliative radiotherapy. Routinely administered a long and a short irradiation schedule have been compared retrospectively in terms of survival and palliative response in lung cancer patients with brain metastasis. Between January 2001 and December 2004, 28 of 44 consecutive patients who have admitted to our center were treated with a long (3000 cGy/10 fractions/2 weeks) and 16 of 44 patients were treated with a short (2000 cGy/5 fractions/1 week) irradiation schedule. Patient characteristics like age, gender, histopathologic diagnosis and performance status were comparable in both groups. Median survival of the whole population was 3,5 months and survival curves were similar in both groups. In conclusion the more economic and easier short irradiation schedule can be preferred collectively in this big patient population.

Keywords:

Lung Neoplasms, Neoplasm Metastasis, Radiotherapy, Brain Neoplasms, Palliative Care, Survival Rate,

PDF

___

1. Posner JB. Management of central nervous system metastases. Semin Oncol, 1977; 4: 81-91.
2. Perez CA, Brady LW. Principles and Practice of Radiation Oncology, 3rd Edition. Philadelphia: Lippincott-Raven, 1998: 2190.
3. Zimm S, Wampler GL, Stablein D, et al. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer, 1981; 48: 384-394.
4. Fleckenstein K, Hof H, Lohr F, et al. Prognostic factors for brain metastases after whole brain radiotherapy. Data from a single institution. Strahlenther Onkol, 2004; 180: 268-273.
5. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys, 1994; 29: 711-717.
6. Diener-West M, Dobbins TW, Phillips TL. Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using RTOG study 7916. Int J Radiat Oncol Biol Phys, 1989; 16: 669-673.
7. Kocher M, Muller RP, Staar S. et al. Long-term survival after brain metastases in breast cancer. Strahlenther Onkol, 1995; 171: 290-295.
8. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys, 1997; 37: 745-751.
9. Lutterbach J, Bartelt S, Ostertag C. Long-term survival in patients with brain metastases. J Cancer Res Clin Oncol, 2002; 128: 417-425.
10. Lutterbach J, Bartelt S, Stancu E, et al. Patients with brain metastases: hope for recursive partitioning analysis (RPA) class 3. Radiother Oncol, 2002; 63: 339-345.
11. Panagiotou IE, Brountzos EN, Kelekis DA, et al. Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome. Neoplasma, 2005; 52: 150-158.
12. Poon AN, Ho SS, Yeo W, et al. Brain metastasis responding to gefitinib alone. Oncology, 2004; 67: 174-178.
13. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA, 1998; 280: 1485-1489.
14. Bogart JA, Ungureanu C, Shihadeh E, et al. Resection and permanent I-125 brachytherapy without whole brain irradiation for solitary brain metastasis from non-small cell lung carcinoma. J Neurooncol, 1999; 44: 53-57.
15. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet, 2004; 363: 1665- 1672.
16. Lohr F, Pirzkall A, Hof H, et al. Adjuvant treatment of brain metastases. Semin Surg Oncol, 2001; 20: 50-56.
17. Cairncross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. Ann Neurol, 1980; 7: 529-541.
18. Lagerwaard FJ, Levendag PC, Nowak PJ, et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys, 1999; 43: 795-803.
19. Yaneva MP. Radiotherapy of brain metastases in lung cancer. Folia Med (Plovdiv), 2000; 42: 34-36.
20. Coia LR. The role of radiation therapy in the treatment of brain metastases. Int J Radiat Oncol Biol Phys, 1992; 23: 229-238.
21. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004 May 22;363(9422):1665-1672.
22. Epstein BE, Scott CB, Sause WT, et al. Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater. Results of Radiation Therapy Oncology Group 85-28. Cancer. 1993 Feb 15;71:1362-1367.